Showing results (641-650 of 673) with videos related to

Sort By:
Pageof 68
Nature Medicine|March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialRaajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Blood Advances|November 24, 2020
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosisAaron T Gerds, Michael R Savona, Bart L Scott, et al.
The New England Journal of Medicine|October 11, 2018
Classification and Personalized Prognosis in Myeloproliferative NeoplasmsJacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
American Journal of Hematology|November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesEmanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.
The New England Journal of Medicine|April 5, 2018
Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant EffusionRahul Bhatnagar, Emma K Keenan, Anna J Morley, et al.
Leukemia|July 18, 2013
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) studyJ V Jovanovic, A Ivey, A M Vannucchi, et al.
Pageof 68